Chris Froome cleared in anti-doping investigation
Chris Froome is cleared to ride in the Tour de France after cycling’s governing body announced that it had closed its case against the Team Sky rider.
Froome’s urine sample taken at last year’s Vuelta a Espana contained double the permitted levels of the asthma drug Salbutamol.
After 10 months of investigation, the UCI said in a statement:
‘The UCI has considered all the relevant evidence in detail (in consultation with its own experts and experts from WADA). On 28 June 2018, WADA informed the UCI that it would accept, based on the specific facts of the case, that Mr Froome’s sample results do not constitute an Adverse Analytical Finding (AAF). In light of WADA’s unparalleled access to information and authorship of the salbutamol regime, the UCI has decided, based on WADA’s position, to close the proceedings against Mr Froome. ‘
Chris Froome said:
‘I have never doubted that this case would be dismissed for the simple reason that I have known throughout I did nothing wrong. I have suffered with asthma since childhood. I know exactly what the rules are regarding my asthma medication and I only ever use my puffer to manage my symptoms within the permissible limits.’
Froome could have faced a two-year ban and the loss of his Vuelta title if he had been found guilty.
This Saturday, he will be leading Team Sky at the Tour de France, with Welsh duo Geraint Thomas and Luke Rowe among the support riders. Froome wants to make history with a fifth Tour de France win and fourth consecutive Grand Tour.
Please click here to view the UCI's press release.